Addiction Treatment: Orexo Receives US FDA Approval for Zubsolv for Treatment of Opioid Dependence – pharmabiz.com
Orexo receives US FDA approval for Zubsolv for treatment of opioid dependence – pharmabiz.com
Filed under: Addiction Treatment
|
Orexo receives US FDA approval for Zubsolv for treatment of opioid dependence
pharmabiz.com Orexo US, Inc., an emerging specialty pharmaceutical company marketing improved treatments for opioid dependence using proprietary drug delivery technology, has received approval from the US Food and Drug Administration (FDA) for Zubsolv … |
Addiction Treatment – Google News
FDA Approves New Treatment for Opioid Dependence – Medscape
Filed under: Addiction Treatment
|
FDA Approves New Treatment for Opioid Dependence
Medscape The US Food and Drug Administration (FDA) has approved Zubsolv (buprenorphine/naloxone, Orexo AB) for maintenance treatment of opioid dependence. Zubsolv is a once-daily, sublingual tablet with a formulation of buprenorphine and naloxone that fully … |
Addiction Treatment – Google News
US FDA Approves Zubsolv(R) for the Maintenance Treatment of Opioid … – Wall Street Journal
Filed under: Addiction Treatment
|
US FDA Approves Zubsolv(R) for the Maintenance Treatment of Opioid …
Wall Street Journal Treatment should be initiated under the direction of physicians who are certified under the Drug Addiction Treatment Act of 2000, and who have been assigned a unique identification number ("X" number). Zubsolv sublingual tablet can be abused in a … |
Addiction Treatment – Google News
More Addiction Treatment Information…